TFF Pharmaceuticals, Inc. (TFFP)
NASDAQ: TFFP · Real-Time Price · USD
0.340
-0.010 (-2.91%)
At close: Nov 22, 2024, 4:00 PM
0.310
-0.030 (-8.91%)
After-hours: Nov 22, 2024, 7:59 PM EST
TFF Pharmaceuticals Revenue
TFF Pharmaceuticals had revenue of $193.39K in the quarter ending September 30, 2024, a decrease of -17.62%. This brings the company's revenue in the last twelve months to $1.16M, up 24.55% year-over-year. In the year 2023, TFF Pharmaceuticals had annual revenue of $733.87K with 48.02% growth.
Revenue (ttm)
$1.16M
Revenue Growth
+24.55%
P/S Ratio
0.94
Revenue / Employee
$61,116
Employees
19
Market Cap
1.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LogicMark | 10.08M |
Tenon Medical | 3.32M |
China SXT Pharmaceuticals | 1.93M |
SciSparc | 1.75M |
Catheter Precision | 399.00K |
TFFP News
- 8 days ago - TFF Pharmaceuticals Announces It Will Wind Down Operations - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization - GlobeNewsWire
- 3 months ago - TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 5 months ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 6 months ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 6 months ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire
- 6 months ago - TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire